Strategic OEM Partnerships Position CircuLite as a complementary platform for large cardiovascular OEMs. The CE Mark trial and the world’s smallest surgically implanted micro-pump can unlock co-development, distribution, or licensing deals with potential partners like Getinge, LivaNova, Abbott, Medtronic, and Abiomed to accelerate hospital adoption.

European Expansion Readiness With a CE Mark clinical trial underway, there is a clear path to European hospital networks. Target early engagement with EU distributors, cardiac centers, and system integrators, aligning sales timelines with European procurement cycles and upcoming regulatory milestones.

Heart Failure Targeting The minimally invasive circulatory support approach targets chronic heart failure patients in hospital settings. Focus on high-volume cardiology and cardiac surgery centers to demonstrate clinical value, reduce admissions, and build compelling case studies that drive payer and provider adoption.

Channel Partnerships Scale A lean team structure suggests leveraging channel partnerships and OEM distribution to scale faster. Prioritize co-selling and licensing strategies with larger medical device players to reach global hospital networks and maximize revenue potential.

Portfolio Expansion Opportunities Future products including endovascular, right-heart, and pediatric pumps expand addressable markets and create cross-sell opportunities. Engage pediatric centers, specialized cardiac programs, and trauma or critical care units with bundled offerings and clinical evidence to drive multi-system adoption.